Recombinant Human Wnt3a V3

Catalog No : PMK2101

Known As: Wnt Surrogate-Fc Fusion Protein; Wnt Surrogate

PROPERTIES

Description	Recombinant Human Wnt3a V3 is a Wnt Surrogate Protein and is produced by our Mammalian expression system
Formulation	Supplied as a 0.2 μm filtered solution of 25mM Tris-HCl, 500mM NaCl, pH8.2.
Size	10μg/50μg/500μg/1mg
Purity	> 95%
Endotoxin	< 0.01 EU/μg as determined by LAL test.
Predicted Mol Mass	58.5kDa
Apparent Mol Mass	66-73kDa, reducing conditions.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Background	Wnt-3a is one of 19 vertebrate members of the Wingless-type MMTV integration site (Wnt) family of highly conserved cysteine-rich secreted glycoproteins important for normal developmental processes. WNT signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including bone, liver, skin, stomach, intestine, lung, kidney, central nervous system, mammary gland, taste bud, ovary, cochlea, and vessels among many others. Modulation of WNT signaling pathways has potential for treatment of degenerative diseases and tissue injuries. And they signal through FZD1-10 and LRP5 or 6, two families of receptors. Endogenous WNTs bind to multiple FZDs and are heavily modified posttranslationally, making them difficult to manufacture consistently. WNT surrogate molecules phenocopied endogenous ligand activities in in vitro reporter assays and intestine organoid functional assays. WNT surrogate molecules can be selective for individual FZD or a subfamily of FZDs in combination with LRP5 or LRP6, depending on the binder specificities.